English

Protagenic Therapeutics, Inc.\new

EDGAR

ATRN Quarterly report (10-Q) · filed 2026-08-19

Annual consolidated revenue for 2026: about USD 0, using the latest reported figures. The previous period, 2025, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

266 thousand USD

2026 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -2806800 USD Source
Operating Cash Flow: -3072333 USD Source

Cash and cash equivalents: 192 thousand USD 2021-03-31 Source
Exact value

191674 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1.81 million shares 2026-06-30 Source
Exact value

1810208 shares

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-19.

Financial data available through: 2026-03-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2026-03-31
Operating income: 11 of 11 periods available· newest 2026-03-31
Net income: 11 of 11 periods available· newest 2026-03-31
Operating cash flow: 11 of 11 periods available· newest 2026-03-31
capital expenditure: No compatible figures in this window
Total assets: 8 of 11 periods available· newest 2026-03-31
Total liabilities: 7 of 11 periods available· newest 2026-03-31
Current assets: 8 of 11 periods available· newest 2026-03-31
Current liabilities: 8 of 11 periods available· newest 2026-03-31
Cash and cash equivalents: 2 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2026-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-04-01 – 2025-03-31
Current period

USD 0

2025-04-01 – 2026-03-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
0 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Protagenic Therapeutics, Inc.\new · 2026-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1912064 Filing: 000149315226038255 Input fundies:Revenue: 0 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1912225 Filing: 000149315226038255
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 4.96 million

Prior period

−USD 3.59 million

2024-04-01 – 2025-03-31
Current period

USD 1.37 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

1367977 − -3591858 = 4959835 USD

-3591858 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
1367977 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Protagenic Therapeutics, Inc.\new · 2026-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Year-over-year change in Net income: 4959835 USD Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 1367977 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1548877 Filing: 000149315226038255 Input fundies:NetIncome: -3591858 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1549241 Filing: 000149315226038255
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.04 million

Prior period

−USD 1.77 million

2024-04-01 – 2025-03-31
Current period

−USD 2.81 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-2806800 − -1768908 = -1037892 USD

-1768908 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-2806800 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Protagenic Therapeutics, Inc.\new · 2026-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Year-over-year change in Operating cash flow: -1037892 USD Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -2806800 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1562627 Filing: 000149315226038255 Input fundies:OperatingCashFlow: -1768908 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1563041 Filing: 000149315226038255
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-04-01 – 2026-03-31

Revenue USD 0
Operating costs Derived USD 4.5 million
Operating income −USD 4.5 million
Tax, interest and other Derived −USD 5.87 million
Net income USD 1.37 million

Cash

Operating cash flow −USD 2.81 million
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.
2026 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	2551611 Derived	-2551611	-2876 Derived	-2548735	Unavailable	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -2551611 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -2548735 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -1348779 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	4140413 Derived	-4140413	382521 Derived	-4522934	Unavailable	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -4140413 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -4522934 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -2798614 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	3557788 Derived	-3557788	-2283 Derived	-3555505	Unavailable	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -3557788 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -3555505 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -1993814 USD Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	4526974 Derived	-4526974	473523 Derived	-5000497	Unavailable	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -4526974 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -5000497 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -3703776 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	5700950 Derived	-5700950	-175606 Derived	-5525344	Unavailable	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -5700950 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -5525344 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -4216517 USD Inspect Operating Cash Flow Open source
2025 2024-04-01 – 2025-03-31	2593561 Derived	-2593561	998297 Derived	-3591858	Unavailable	Source 2024-04-01 – 2025-03-31: 0 USD Inspect Revenue Open source 2024-04-01 – 2025-03-31: -2593561 USD Inspect Operating Income Open source 2024-04-01 – 2025-03-31: -3591858 USD Inspect Net Income Open source 2024-04-01 – 2025-03-31: -1768908 USD Inspect Operating Cash Flow Open source
2026 2025-04-01 – 2026-03-31	4503710 Derived	-4503710	-5871687 Derived	1367977	Unavailable	Source 2025-04-01 – 2026-03-31: 0 USD Inspect Revenue Open source 2025-04-01 – 2026-03-31: -4503710 USD Inspect Operating Income Open source 2025-04-01 – 2026-03-31: 1367977 USD Inspect Net Income Open source 2025-04-01 – 2026-03-31: -2806800 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2026

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source
20242024-12-31	Revenue	Revenue: 0 Open source
20252025-03-31	Revenue	Revenue: 0 Open source
20262026-03-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20252025-03-31	Year over year	No prior comparable period	Revenue: 0 Open source
20262026-03-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -2551611 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -4140413 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -3557788 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -4526974 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -5700950 Open source Revenue: 0 Open source
20252025-03-31	Operating margin	Not reported	Operating Income: -2593561 Open source Revenue: 0 Open source
20262026-03-31	Operating margin	Not reported	Operating Income: -4503710 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -2548735 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -4522934 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -3555505 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -5000497 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -5525344 Open source Revenue: 0 Open source
20252025-03-31	Net margin	Not reported	Net Income: -3591858 Open source Revenue: 0 Open source
20262026-03-31	Net margin	Not reported	Net Income: 1367977 Open source Revenue: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1348779 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -2798614 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1993814 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -3703776 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -4216517 Open source
20252025-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -1768908 Open source
20262026-03-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -2806800 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -2.8M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-1348779	Operating Cash Flow: -1348779 Open source
20212021-12-31	Operating cash flow	-2798614	Operating Cash Flow: -2798614 Open source
20222022-12-31	Operating cash flow	-1993814	Operating Cash Flow: -1993814 Open source
20232023-12-31	Operating cash flow	-3703776	Operating Cash Flow: -3703776 Open source
20242024-12-31	Operating cash flow	-4216517	Operating Cash Flow: -4216517 Open source
20252025-03-31	Operating cash flow	-1768908	Operating Cash Flow: -1768908 Open source
20262026-03-31	Operating cash flow	-2806800	Operating Cash Flow: -2806800 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1348779 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -2798614 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1993814 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -3703776 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -4216517 Open source
20252025-03-31	Free cash flow	Unavailable	Operating Cash Flow: -1768908 Open source
20262026-03-31	Free cash flow	Unavailable	Operating Cash Flow: -2806800 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.3% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	230.8%	Total Liabilities: 2028983 Open source Total Assets: 879247 Open source
20212021-12-31	Liabilities / assets	10.1%	Total Liabilities: 1117968 Open source Total Assets: 11059923 Open source
20222022-12-31	Liabilities / assets	13.9%	Total Liabilities: 1119862 Open source Total Assets: 8037420 Open source
20232023-12-31	Liabilities / assets	15.2%	Total Liabilities: 655252 Open source Total Assets: 4323369 Open source
20242024-12-31	Liabilities / assets	48.2%	Total Liabilities: 942759 Open source Total Assets: 1955913 Open source
20252025-03-31	Liabilities / assets	5,659.3%	Total Liabilities: 5042052 Open source Total Assets: 89093 Open source
20262026-03-31	Liabilities / assets	28.3%	Total Liabilities: 1031479 Open source Total Assets: 3650370 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.5× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	1.34×	Current Assets: 879247 Open source Current Liabilities: 655187 Open source
20212021-12-31	Current assets / current liabilities	13.83×	Current Assets: 11059923 Open source Current Liabilities: 799535 Open source
20222022-12-31	Current assets / current liabilities	7.18×	Current Assets: 8035645 Open source Current Liabilities: 1119862 Open source
20232023-12-31	Current assets / current liabilities	6.41×	Current Assets: 4200037 Open source Current Liabilities: 655252 Open source
20242024-12-31	Current assets / current liabilities	2×	Current Assets: 1882867 Open source Current Liabilities: 942759 Open source
20252025-03-31	Current assets / current liabilities	0.02×	Current Assets: 89093 Open source Current Liabilities: 5042052 Open source
20262026-03-31	Current assets / current liabilities	1.5×	Current Assets: 1542586 Open source Current Liabilities: 1031479 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 2.26 million Exact value Exact value: -2259636 USD 2017-01-01 – 2017-12-31: -2259636 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2017-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -2259636 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2259636 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315219004288/ptix-20181231.xml#483343 Filing: 000149315219004288 The citation records this snapshot. The page link may show a newer release later.	−USD 1.38 million Exact value Exact value: -1380089 USD 2017-01-01 – 2017-12-31: -1380089 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2017-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -1380089 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1380089 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315219004288/ptix-20181231.xml#488543 Filing: 000149315219004288 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 2.56 million Exact value Exact value: -2557531 USD 2018-01-01 – 2018-12-31: -2557531 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2018-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -2557531 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2557531 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315220007286/ptix-20191231.xml#92268 Filing: 000149315220007286 The citation records this snapshot. The page link may show a newer release later.	−USD 1.07 million Exact value Exact value: -1071188 USD 2018-01-01 – 2018-12-31: -1071188 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2018-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -1071188 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1071188 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315220007286/ptix-20191231.xml#96283 Filing: 000149315220007286 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 1.75 million Exact value Exact value: -1750911 USD 2019-01-01 – 2019-12-31: -1750911 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2019-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -1750911 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1750911 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315221006756/ptix-20201231.xml#117038 Filing: 000149315221006756 The citation records this snapshot. The page link may show a newer release later.	−USD 487,990 Exact value Exact value: -487990 USD 2019-01-01 – 2019-12-31: -487990 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2019-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -487990 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -487990 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315221006756/ptix-20201231.xml#495821 Filing: 000149315221006756 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 2.55 million Exact value Exact value: -2548735 USD 2020-01-01 – 2020-12-31: -2548735 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2020-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -2548735 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2548735 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315222009370/form10-k.htm#1341915 Filing: 000149315222009370 The citation records this snapshot. The page link may show a newer release later.	−USD 1.35 million Exact value Exact value: -1348779 USD 2020-01-01 – 2020-12-31: -1348779 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2020-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -1348779 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1348779 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315222009370/form10-k.htm#1350583 Filing: 000149315222009370 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 4.52 million Exact value Exact value: -4522934 USD 2021-01-01 – 2021-12-31: -4522934 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2021-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -4522934 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4522934 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315223010152/form10-k.htm#1236291 Filing: 000149315223010152 The citation records this snapshot. The page link may show a newer release later.	−USD 2.8 million Exact value Exact value: -2798614 USD 2021-01-01 – 2021-12-31: -2798614 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2021-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -2798614 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2798614 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315223010152/form10-k.htm#1244990 Filing: 000149315223010152 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 3.56 million Exact value Exact value: -3555505 USD 2022-01-01 – 2022-12-31: -3555505 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2022-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -3555505 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3555505 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315224019018/form10-ka.htm#1227282 Filing: 000149315224019018 The citation records this snapshot. The page link may show a newer release later.	−USD 1.99 million Exact value Exact value: -1993814 USD 2022-01-01 – 2022-12-31: -1993814 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2022-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -1993814 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1993814 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315224019018/form10-ka.htm#1235488 Filing: 000149315224019018 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 5 million Exact value Exact value: -5000497 USD 2023-01-01 – 2023-12-31: -5000497 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2023-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -5000497 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5000497 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000164117225001600/form10-k.htm#1473431 Filing: 000164117225001600 The citation records this snapshot. The page link may show a newer release later.	−USD 3.7 million Exact value Exact value: -3703776 USD 2023-01-01 – 2023-12-31: -3703776 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2023-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -3703776 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3703776 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000164117225001600/form10-k.htm#1490387 Filing: 000164117225001600 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 5.53 million Exact value Exact value: -5525344 USD 2024-01-01 – 2024-12-31: -5525344 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2024-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -5525344 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5525344 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000164117225001600/form10-k.htm#1472807 Filing: 000164117225001600 The citation records this snapshot. The page link may show a newer release later.	−USD 4.22 million Exact value Exact value: -4216517 USD 2024-01-01 – 2024-12-31: -4216517 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2024-12-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -4216517 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4216517 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000164117225001600/form10-k.htm#1489781 Filing: 000164117225001600 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2024-04-01 – 2025-03-31	−USD 3.59 million Exact value Exact value: -3591858 USD 2024-04-01 – 2025-03-31: -3591858 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2025-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: -3591858 USD Concept: fundies:NetIncome Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:NetIncome: -3591858 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1549241 Filing: 000149315226038255 The citation records this snapshot. The page link may show a newer release later.	−USD 1.77 million Exact value Exact value: -1768908 USD 2024-04-01 – 2025-03-31: -1768908 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2025-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -1768908 USD Concept: fundies:OperatingCashFlow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1768908 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1563041 Filing: 000149315226038255 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2026 2025-04-01 – 2026-03-31	USD 1.37 million Exact value Exact value: 1367977 USD 2025-04-01 – 2026-03-31: 1367977 USD Inspect Net Income Open source Share or cite Citation for Net Income · Protagenic Therapeutics, Inc.\new · 2026-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Net Income: 1367977 USD Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3ANetIncome&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:NetIncome: 1367977 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1548877 Filing: 000149315226038255 The citation records this snapshot. The page link may show a newer release later.	−USD 2.81 million Exact value Exact value: -2806800 USD 2025-04-01 – 2026-03-31: -2806800 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Protagenic Therapeutics, Inc.\new · 2026-03-31 Protagenic Therapeutics, Inc.\new (edgar:1022899) Operating Cash Flow: -2806800 USD Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T13:44:33Z Snapshot: dc52f1e850f3aca2e9954766e2d146897c9c315a1a7146a6c7ae455e5aa84713 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1022899/explain?concept=fundies%3AOperatingCashFlow&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2806800 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1022899/000149315226038255/form10-k.htm#1562627 Filing: 000149315226038255 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

123 filings · 2,939 latest values · 2,937 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001022899, 1022899, ATRN, PTIX, atrn, edgar:1022899, ptix

Also known as ATRINSIC, INC., Atrinsic, Inc., MILLBROOK PRESS INC, MPLC, Inc., NEW MOTION, INC., Protagenic Therapeutics, Inc.\new

Protagenic Therapeutics, Inc.\new

Latest quarter

Revenue

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2026 2025-04-01 – 2026-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation